Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
Nature Reviews. Clinical Oncology
|
October 29, 2014
Medulloblastoma-translating discoveries from the bench to the bedside
Amar J Gajjar, Giles W Robinson
Nature Reviews. Clinical Oncology
|
June 29, 2011
Challenging issues in pediatric oncology
Ching-Hon Pui, Amar J Gajjar, Javier R Kane, et al.
Journal of Neurosurgery. Pediatrics
|
September 3, 2011
Resection of infantile brain tumors after neoadjuvant chemotherapy: the St. Jude experience
Mark Van Poppel, Paul Klimo, Mariko Dewire, et al.
Pediatric Blood & Cancer
|
September 4, 2023
Topotecan clearance based on a single sample and a population pharmacokinetic model: Application to a pediatric high-risk neuroblastoma clinical trial
Olivia Campagne, Huiyun Wu, Jianrong Wu, et al.
Neurosurgery
|
March 23, 2017
Pineoblastoma-The Experience at St. Jude Children's Research Hospital
Kara A Parikh, Garrett T Venable, Brent A Orr, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
April 8, 2016
Population Pharmacokinetics of Oral Topotecan in Infants and Very Young Children with Brain Tumors Demonstrates a Role of ABCG2 rs4148157 on the Absorption Rate Constant
Jessica K Roberts, Anna V Birg, Tong Lin, et al.
Neuro-Oncology
|
May 26, 2017
Disrupted development and integrity of frontal white matter in patients treated for pediatric medulloblastoma
John O Glass, Robert J Ogg, Jung W Hyun, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 3, 2004
Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors
Najat C Daw, Victor M Santana, Lisa C Iacono, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 2006
Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors
Wayne L Furman, Kristine R Crews, Catherine Billups, et al.
JAMA
|
October 22, 2002
Risk factors for traumatic and bloody lumbar puncture in children with acute lymphoblastic leukemia
Scott C Howard, Amar J Gajjar, Cheng Cheng, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
Nature Reviews. Clinical Oncology
|
October 29, 2014
Medulloblastoma-translating discoveries from the bench to the bedside
Amar J Gajjar, Giles W Robinson
Nature Reviews. Clinical Oncology
|
June 29, 2011
Challenging issues in pediatric oncology
Ching-Hon Pui, Amar J Gajjar, Javier R Kane, et al.
Journal of Neurosurgery. Pediatrics
|
September 3, 2011
Resection of infantile brain tumors after neoadjuvant chemotherapy: the St. Jude experience
Mark Van Poppel, Paul Klimo, Mariko Dewire, et al.
Pediatric Blood & Cancer
|
September 4, 2023
Topotecan clearance based on a single sample and a population pharmacokinetic model: Application to a pediatric high-risk neuroblastoma clinical trial
Olivia Campagne, Huiyun Wu, Jianrong Wu, et al.
Neurosurgery
|
March 23, 2017
Pineoblastoma-The Experience at St. Jude Children's Research Hospital
Kara A Parikh, Garrett T Venable, Brent A Orr, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
April 8, 2016
Population Pharmacokinetics of Oral Topotecan in Infants and Very Young Children with Brain Tumors Demonstrates a Role of ABCG2 rs4148157 on the Absorption Rate Constant
Jessica K Roberts, Anna V Birg, Tong Lin, et al.
Neuro-Oncology
|
May 26, 2017
Disrupted development and integrity of frontal white matter in patients treated for pediatric medulloblastoma
John O Glass, Robert J Ogg, Jung W Hyun, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 3, 2004
Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors
Najat C Daw, Victor M Santana, Lisa C Iacono, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 2006
Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors
Wayne L Furman, Kristine R Crews, Catherine Billups, et al.
JAMA
|
October 22, 2002
Risk factors for traumatic and bloody lumbar puncture in children with acute lymphoblastic leukemia
Scott C Howard, Amar J Gajjar, Cheng Cheng, et al.
Page
of 2